{
  "drugid": "RxNorm:37790",
  "drugname": "tenoxicam",
  "guidelinename": "CYP2C9 and NSAIDs",
  "url": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/",
  "guidelinepharmgkbids": [
    "PA166191841"
  ],
  "citations": [
    {
      "pmid": "32189324",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs.",
      "authors": [
        "Theken Katherine N",
        "Lee Craig R",
        "Gong Li",
        "Caudle Kelly E",
        "Formea Christine M",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Agúndez José A G",
        "Grosser Tilo"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2020
    }
  ],
  "recommendations": [
    {
      "implications": {
        "CYP2C9": "Mildly reduced metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
      "classification": "Moderate",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2C9": "1.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.5"
      },
      "comments": "IMs might have a higher than normal risk of adverse events especially in individuals with other factors affecting clearance of these drugs such as hepatic impairment or advanced age.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "n/a"
      },
      "drugrecommendation": "No recommendation",
      "classification": "No Recommendation",
      "phenotypes": {
        "CYP2C9": "Indeterminate"
      },
      "activityscore": {
        "CYP2C9": "n/a"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "n/a"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      },
      "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2C9": "0.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.0"
      },
      "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Significantly reduced metabolism and prolonged half-life; higher plasma concentrations may increase probability and/or severity of toxicities"
      },
      "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Poor Metabolizer"
      },
      "activityscore": {
        "CYP2C9": "0.5"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "0.5"
      },
      "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Moderately reduced metabolism; higher plasma concentrations may increase probability of toxicities"
      },
      "drugrecommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
      "classification": "Optional",
      "phenotypes": {
        "CYP2C9": "Intermediate Metabolizer"
      },
      "activityscore": {
        "CYP2C9": "1.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "1.0"
      },
      "comments": "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity.",
      "population": "general",
      "genotypes": null
    },
    {
      "implications": {
        "CYP2C9": "Normal metabolism"
      },
      "drugrecommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
      "classification": "Strong",
      "phenotypes": {
        "CYP2C9": "Normal Metabolizer"
      },
      "activityscore": {
        "CYP2C9": "2.0"
      },
      "allelestatus": {},
      "lookupkey": {
        "CYP2C9": "2.0"
      },
      "comments": "n/a",
      "population": "general",
      "genotypes": null
    }
  ],
  "genes": [
    "CYP2C9"
  ],
  "notesonusage": null,
  "cpicVersion": "v1.30.0",
  "source": "CPIC"
}